A Contemporary Review of the Treatment of Medullary Thyroid Carcinoma in the Era of New Drug Therapies

Medullary thyroid cancer (MTC) is a rare neuroendocrine tumor that can be sporadic or inherited and is often associated with mutations in the RET (Rearranged during Transfection) oncogene. The primary treatment for MTC is surgical resection of all suspected disease, but recent advances in targeted t...

Full description

Saved in:
Bibliographic Details
Published inSurgical oncology clinics of North America Vol. 32; no. 2; p. 233
Main Authors Seib, Carolyn D, Beck, Thomas C, Kebebew, Electron
Format Journal Article
LanguageEnglish
Published United States 01.04.2023
Subjects
Carcinoma, Medullary - genetics
Carcinoma, Medullary - pathology
Carcinoma, Medullary - surgery
Carcinoma, Neuroendocrine - drug therapy
Carcinoma, Neuroendocrine - genetics
Humans
Proto-Oncogene Mas
Thyroid Neoplasms - drug therapy
Thyroid Neoplasms - genetics
RET
Lymph node dissection
Targeted therapy
Neuroendocrine tumor
Thyroidectomy
Medullary thyroid cancer
Medullary thyroid carcinoma
Online AccessGet more information

Cover

More Information
Summary:Medullary thyroid cancer (MTC) is a rare neuroendocrine tumor that can be sporadic or inherited and is often associated with mutations in the RET (Rearranged during Transfection) oncogene. The primary treatment for MTC is surgical resection of all suspected disease, but recent advances in targeted therapies for MTC, including the selective RET inhibitors selpercatinib and pralsetinib, have led to changes in the management of patients with locally advanced, metastatic, or recurrent MTC. In this article, we review updates on the evaluation and management of patients with MTC, focusing on new and emerging therapies that are likely to improve patient outcomes.
ISSN:1558-5042
DOI:10.1016/j.soc.2022.10.002